Latest Conference Articles

Carlton Brown Describes Key Messages of the ONS Congress

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Oral oncolytics are frequently used in cancer treatment and they make up approximately 25% of the medications in the oncology pipeline

Honorary Mistress of Ceremonies Cynthia Nixon kicked off the ONS 36th Annual Congress Cure magazine Extraordinary Healer Award with a rousing tribute

Lymphedema is the treatment-induced buildup of extra lymph fluid in tissues that causes discomforting and potentially debilitating swelling of the limbs

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Social media programs allow oncology nurses to network, share information, and learn evidence-based practices

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Elizabeth Blasiak on the Significance of the ONS Congress

Prostate cancer affects 1 of every 6 men in the United States

Traditional, linear regimen of prostate cancer treatment may need to be reexamined as oncologists learn new ways to incorporate new therapies

Initial clinical findings indicate that results with radiotherapies sometime improve when combined with immunotherapy

Immunotherapies again made headlines in oncology last month

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized high-risk prostate cancer patients

Screening for prostate cancer does work, despite controversy about its efficacy, according to IPCC Co-chair Leonard G. Gomella

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

As research into novel vaccine approaches for treating advanced prostate cancer continues...

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer

In this podcast, Maisam Fazel, FRCS, MS, MB BChir, discusses his research into a checklist for breast cancer surgeons.

Dr. Daniel Osman, director of the Miami Breast Cancer Conference, on Designing the Program for the MBCC

Maisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training

As the number of breast cancer survivors grows, so does the emphasis on establishing individualized survivorship plans

Preoperative neoadjuvant systemic therapy can be valuable for patients even if they do not achieve a pathologic complete response

With thousands of clinical trials in play, many oncology specialists are reluctant to embrace findings from newly-released studies

Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy

Personalized treatment in oncology is a popular concept these days, but the goal remains elusive

It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ